Membranoproliferative glomerulonephritis primary prevention: Difference between revisions
No edit summary |
Aditya Ganti (talk | contribs) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Membranoproliferative glomerulonephritis}} | |||
{{CMG}} {{AE}} {{JSS}} | {{CMG}} {{AE}} {{JSS}} | ||
== Overview == | == Overview == | ||
Effective measures for primary prevention of membranous glomerulonephritis include vaccination against [[hepatitis B]] and [[hepatitis C]]. | |||
==Primary Prevention== | ==Primary Prevention== | ||
Effective measures for primary prevention of membranous glomerulonephritis include:<ref name="LaiLi1991">{{cite journal|last1=Lai|first1=Kar Neng|last2=Li|first2=Philip K.T.|last3=Lui|first3=Siu Fai|last4=Au|first4=Tak Cheong|last5=Tam|first5=John S.L.|last6=Tong|first6=Kwok Lung|last7=Lai|first7=Fernand Mac-Moune|title=Membranous Nephropathy Related to Hepatitis B Virus in Adults|journal=New England Journal of Medicine|volume=324|issue=21|year=1991|pages=1457–1463|issn=0028-4793|doi=10.1056/NEJM199105233242103}}</ref><ref name="pmid4069286">{{cite journal |vauthors=Gyapay G, Jeney A, Lapis K |title=Drug action and chromatin structure. I. Adriamycin binding to core particle of nucleosomes and subsequent enhanced DNA fragmentation induced by micrococcal nuclease |journal=Neoplasma |volume=32 |issue=5 |pages=521–8 |date=1985 |pmid=4069286 |doi= |url=}}</ref> | |||
*Vaccine against [[hepatitis B]] and [[hepatitis C]]. | |||
==References== | ==References== | ||
Latest revision as of 20:32, 6 August 2018
|
Membranoproliferative glomerulonephritis Microchapters |
|
Differentiating Membranoproliferative glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Membranoproliferative glomerulonephritis primary prevention On the Web |
|
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis primary prevention |
|
FDA on Membranoproliferative glomerulonephritis primary prevention |
|
CDC on Membranoproliferative glomerulonephritis primary prevention |
|
Membranoproliferative glomerulonephritis primary prevention in the news |
|
Blogs on Membranoproliferative glomerulonephritis primary prevention |
|
Directions to Hospitals Treating Membranoproliferative glomerulonephritis |
|
Risk calculators and risk factors for Membranoproliferative glomerulonephritis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2]
Overview
Effective measures for primary prevention of membranous glomerulonephritis include vaccination against hepatitis B and hepatitis C.
Primary Prevention
Effective measures for primary prevention of membranous glomerulonephritis include:[1][2]
- Vaccine against hepatitis B and hepatitis C.
References
- ↑ Lai, Kar Neng; Li, Philip K.T.; Lui, Siu Fai; Au, Tak Cheong; Tam, John S.L.; Tong, Kwok Lung; Lai, Fernand Mac-Moune (1991). "Membranous Nephropathy Related to Hepatitis B Virus in Adults". New England Journal of Medicine. 324 (21): 1457–1463. doi:10.1056/NEJM199105233242103. ISSN 0028-4793.
- ↑ Gyapay G, Jeney A, Lapis K (1985). "Drug action and chromatin structure. I. Adriamycin binding to core particle of nucleosomes and subsequent enhanced DNA fragmentation induced by micrococcal nuclease". Neoplasma. 32 (5): 521–8. PMID 4069286.